In the news

I've seen it said before that year-ahead predictions are like weather reports: Everyone reads them, but almost no one looks back later to see whether they were accurate. Still, since when has that stopped anyone from indulging in this pastime as the calendar turns from December to January?

January 31, 2021

The clinical community will increase their use of federated learning approaches to build robust AI models across various institutions, geographies, patient demographics, and medical scanners. The sensitivity and selectivity of these models are outperforming AI models built at a single institution, even when there is copious data to train with. As an added bonus, researchers can collaborate on AI model creation without sharing confidential patient information. Federated learning is also beneficial for building AI models for areas where data is scarce, such as for pediatrics and rare diseases.

December 30, 2020

In November, when the Centers for Medicare & Medicaid Services expanded its acute hospital at home program, it granted immediate waivers to six health systems with extensive experience providing acute hospital care at home, including Brigham and Women’s Hospital in Boston. In a recent interview, David Levine, M.D., M.P.H., who leads Brigham’s program, discussed its plans to scale up and the overall impact of the CMS waiver program.

December 21, 2020

Fierce Healthcare

"In 2021, we'll see a continued move from 'pay-per-pill' to pay-for-value when it comes to drug therapy. This transition will be accelerated by technology such as clinical-grade wearables, remote patient monitoring, patient-facing apps, and AI-powered analytics.

December 21, 2020

Drug Discovery & Development

After smartphones had been around several years, a handful of influential digital-savvy physicians began to boast that they prescribed more apps than drugs. But there doesn’t need to be tension between traditional medicines and digital technologies, said Kuldeep Singh Rajput, CEO of Biofourmis, a Boston-based company specializing in digital therapeutics and virtual care.

December 14, 2020

SoftBank has invested in new health tech companies like digital pharmacy Alto, gene therapy company Encoded Therapeutics, infectious disease diagnostics startup Karius and digital therapeutics company Biofourmis.

December 2, 2020

Biofourmis, a digital therapeutics company, is rolling out an artificial intelligence-driven remote monitoring solution nationally. The solution, Biovitals Hospital@Home, was co-developed with Brigham and Women’s Hospital and can help hospitals quickly deploy a hospital-at-home program.

December 2, 2020

When the coronavirus pandemic forced healthcare outside of hospitals, healthtech captured the attention of venture capitalists who have rushed into investing in the space. US healthtech startups inked more deals than their biopharma counterparts this year through August, which will be an industry first if the trend holds, said Katherine Andersen, head of life science and healthcare relationship banking at Silicon Valley Bank.

October 19, 2020

While COVID-19 has been dominating the healthcare headlines so far in 2020 there have been a number of recent policy and regulatory decisions bearing on the AI/ML market in healthcare. We have been reading quite a bit about the broader slowdown in the market for AI/ML developers since the pandemic began that may be a temporary disruption to some parts of the market.

October 15, 2020

PicnicHealth was founded to help patients with chronic or complex illnesses gain control of their medical records and more effectively navigate their healthcare. The startup expanded with the launch of the PicnicHealth Research Platform, which allows patients to give consent to share their de-identified data with researchers

October 4, 2020

The coronavirus pandemic has been a watershed moment for telehealth — or the use of mobile technology to deliver health-related services, such as remote doctor consultations and patient monitoring — as patients have had to reimagine the ways they seek healthcare.

October 2, 2020

The first six months of the year have painted a picture of extraordinary investor interest in digital health, but no quarter has made a stronger case than the past three months of record-breaking fundraising.

October 2, 2020

Biofourmis (@biofourmis), a company in digital therapeutics that powers personalized predictive care, has announced the completion of a $100 million Series C financing round led by SoftBank Vision Fund 2,[1] with participation by existing investors Openspace Ventures, MassMutual Ventures, Sequoia Capital and EDBI.

September 17, 2020

Earlier this summer, Paris-based Inheart SAS raised $4.2 million to develop a cardiac arrhythmia treatment using medical imaging, AI and digital stimulation. And just this month, Biofourmis Inc. snagged $100 million in series C funds to fuel global expansion of its AI-powered health analytics platform and digital therapeutics pipeline. One of the company’s core products is a 90-day program for heart failure patients that offers medication management, symptom monitoring and caregiver communication.

September 16, 2020

It’s Health in 2 Point 00’s 150th Episode or Sesquicentennial anniversary! On this episode, we have the return of Softbank money—$100M goes to Biofourmis platform for AI & Clinical Trials. Next, Amwell prices their IPO at $14-16 a share, and Grand Rounds raises $175 million led by the Carlyle Group.

September 10, 2020

September 9, 2020

Boston startup Biofourmis, which developed an AI system to spot early signs of COVID-19, raised $100m in a funding round. The company's platform uses AI-based data analytics and biosensors to measure a patient's progress and the effectiveness of medical treatments. 

September 6, 2020

2020 has become the largest funding year in history for digital health, with 24 deals worth more than $100 million apiece recorded, according to a recent Rock Health report. At $4 billion invested in digital health companies during the third quarter of 2020, the year's total funding is now $9.4 billion. This beats the previous largest annual sum of $8.2 billion in investments in 2018, according to the report.

September 6, 2020

Boston-based Biofourmis raises $100 million to further develop its predictive analytics-based remote patient monitoring technology. The company sells data and intervention opportunities to drug companies and offers hospitals a platform for monitoring their newly discharged patients remotely. The company’s products have earned FDA 510(k) clearance for heart failure and arrhythmia detection.

September 4, 2020

Biofourmis, a fast-growing global leader in digital therapeutics that powers personalized predictive care, has announced the completion of a $100 million Series C financing round led by SoftBank Vision Fund 2, with participation by existing investors Openspace Ventures, MassMutual Ventures, Sequoia Capital, and EDBI.

September 3, 2020

Press Release

BOSTON, Sept. 3, 2020 /PRNewswire/ -- Biofourmis, a fast-growing global leader in digital therapeutics that powers personalized predictive care, has announced the completion of a $100 million Series C financing round led by SoftBank Vision Fund 2,^[1] with participation by existing investors Openspace Ventures, MassMutual Ventures, Sequoia Capital and EDBI.

September 3, 2020

Unnecessary patient hospital stays are not only a drain on hospitals’ resources, but also a risk for other patients.

Telehealth can reduce unnecessary patient stays by transferring non-acute patients to their homes, where they can continue receiving appropriate care.

For instance, Biofourmis‘ AI-based remote patient monitoring technology allows stabilized cardiac patients to continue to be cared for at home. Its wearable armband monitors patient vitals 24/7, detects cardiac abnormalities, and alerts clinicians on potential intervention measures.

August 24, 2020

PR Newswire

BOSTON, [U.S.] AND SINGAPORE, July 29 and 30, 2020 – Biofourmis, a global leader in digital therapeutics that powers personalized predictive care, announced today that its Biovitals® Sentinel platform has been deployed by the Ministry of Health (MOH) in Singapore to remotely monitor COVID-19-positive patients to aid in early detection of deterioration and to enable clinicians and nurse teams to intervene early.

July 29, 2020

PR Newswire

TOKYO and BOSTON, July 21, 2020 /PRNewswire/ -- and July 22, 2020 - Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) and Biofourmis, a Boston-based digital therapeutics company, announced that they have partnered to develop a digital solution for the objective assessment of pain associated with endometriosis.

July 21, 2020

Digital monitoring startup and Fierce 15 winner Biofourmis is trying to pair remote monitoring with needed drugs to better monitor patients' health.

May 2, 2020

The fast-moving, Boston-based healthcare analytics and digital therapeutics (DTx) startup snapped up cancer monitoring firm Gaido Health from Takeda Pharmaceuticals in a move that will allow it to expand its portfolio of offerings and the condition areas it operates in, reports MedCity News.

April 17, 2020

In a strange way, healthcare seems to be reverting back to a style that had gone out of fashion many years ago, with an increased amount of health taking place in the home. There are now around 12 million people who are now getting in-home care, from more than 33,000 providers, and last year the annual expenditures for home health care were projected to be over $72 billion.

April 17, 2020

Digital therapeutics company Biofourmis is acquiring Gaido Health from Takeda Pharmaceuticals. Gaido collects information on vital signs through remote monitoring from cancer patients who have been recently discharged from the hospital. Cancer patients are usually immunocompromised and potentially more susceptible to the coronavirus, according to Biofourmis.

April 16, 2020

Remote-monitoring and decision-support startup Biofourmis is set to acquire Takeda Pharmaceuticals’ Gaido Health, an oncology-focused digital tool, for an undisclosed sum. The new cash deal is expected to help Biofourmis further its foothold on the oncology space.

April 16, 2020

Digital therapeutics startup Biofourmis announced Thursday it has acquired Gaido Health from Takeda Pharmaceuticals. Los Angeles-based Gaido Health is an oncology-focused patient monitoring platform that was part of Takeda Digital Ventures, Takeda's corporate technology investment and incubation arm.

April 16, 2020

Already on its second acquisition since it was founded five years ago, Boston-based Biofourmis is growing at a rapid clip. The Boston-based startup uses predictive analytics to forecast problems in patients in heart failure, and is now looking to expand its work to other specialties.

April 16, 2020

Biofourmis, a global leader in digital therapeutics that powers personalized predictive care, announced today it has finalized an agreement to acquire Gaido Health from Takeda Pharmaceuticals, a strategic deal that expands Biofourmis’ portfolio in the oncology space. Gaido Health—a Los Angeles-area based digital therapeutics company focused on the oncology market—was part of Takeda Digital Ventures, Takeda’s corporate technology investment and incubation arm.

April 16, 2020

Digital therapeutics company Biofourmis (Boston, MA) has finalized an agreement to acquire Gaido Health from Takeda Pharmaceuticals, a deal that expands Biofourmis’ portfolio in the oncology space. Gaido Health—a Los Angeles-area based digital therapeutics company focused on the oncology market—was part of Takeda Digital Ventures, Takeda’s corporate technology investment and incubation arm.

April 16, 2020

It was nearly midnight on Valentine’s Day and Kuldeep Singh Rajput, the 28-year-old founder and CEO of Boston startup Biofourmis, was catching up on e-mails when the phone rang. On the other end of the line were four professors and clinicians from the University of Hong Kong, where Biofourmis’s wearable technology and software is used to remotely analyze heart failure patients. The unscheduled call wasn’t cardiac related.

March 24, 2020

Coronavirus is shaking up business and consumer behavior on a massive scale. Both the public and private sectors are scrambling to slow the spread of the illness and contain COVID-19 infections. While the full economic consequences of this black swan event are still unclear, we know that the effects that the virus — and the drastic measures being taken to contain it — are already precipitating change across industries. Here are the top three ways Business Insider Intelligence thinks the pandemic is set to impact healthcare, telecoms & technology, digital media, payments and commerce, fintech, and banking.

March 13, 2020

In an effort to gain new insights about the novel coronavirus sweeping the globe, Boston-based Biofourmis Inc. is leveraging its artificial intelligence (AI)-driven remote monitoring platform to monitor Hong Kong patients diagnosed or suspected of having COVID-19. The remote monitoring and disease surveillance program, which kicked off just a few days ago, is being administered by the University of Hong Kong and includes Biofourmis’ Hong Kong-based joint venture, Harmony Medical Inc.

March 4, 2020

New York-based startup Nomad Health, a company that makes an online platform for healthcare job-seekers and employers, has appointed Liming Zhao as its first chief technology officer. Previously holding similar posts at Frontier Signal (which he cofounded) and Compass, Zhao will be heading up the employment marketplace’s engineering, data science, IT and security efforts, and will also be helping support the company’s expansion into new focus areas.

January 29, 2020

Digital therapeutics company Biofourmis has appointed Jaydev Thakkar as its chief operating officer, and Milan Shah as its chief technology officer. Thakkar joins Boston-based Biofourmis after 14 years at Amgen (NASDAQ: AMGN), where he was most recently director of digital health and innovation. Shah joins from cybersecurity firm Uptycs, where he was co-founder and chief technology officer. Biofourmis is developing software-based therapies and other technologies for various parts of the healthcare system.

January 29, 2020

Boston-based digital therapeutics (DTx) provider Biofourmis on Monday revealed that it both struck a deal with pharma giant Novartis to commercialize a DTx for monitoring heart failure patients and acquired wearable biosensor maker Biovotion, according to MedCity News.

November 19, 2019

Press Release

Biofourmis has been tapped by Novartis to help develop digital therapeutic programs that follow patients home after they’ve been recently diagnosed with heart failure.

November 18, 2019

Biofourmis, a fast-growing global leader in digital therapeutics, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its machine-learning and artificial intelligence (AI)-powered Biovitals™ Analytics Engine as a medical device for ambulatory physiological monitoring.

October 3, 2019

Biofourmis, a fast-growing global leader in digital therapeutics, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its machine-learning and artificial intelligence (AI)-powered Biovitals™ Analytics Engine as a medical device for ambulatory physiological monitoring.

October 3, 2019

The US Food and Drug Administration (FDA) has given the green light for the Biovitals Analytics Engine, a new machine learning and artificial intelligence (AI) device for ambulatory physiological monitoring.

October 3, 2019

A collaboration involving the FDA is set to evaluate new endpoints for heart failure clinical trials. The partners will use wearable devices to assess how heart failure patients function and feel after being discharged from hospitals.

July 16, 2019

Can the pharmaceutical industry use Apple Watches and other wearable sensors to speed drug discovery? That’s what one Singapore startup is claiming, and what the FDA is hoping to find out.

July 16, 2019

An innovative study of patients with heart failure that will monitor functional capacity and quality of life to see if greater emphasis should be placed on these measures in the drug approval process could “advance the science of clinical trial design,” says Kuldeep Singh Rajput, CEO of Biofourmis. His organization has entered a research partnership with the Yale University-Mayo Clinic Center of Excellence in Regulatory Science and Innovation (CERSI). Biofourmis’ mobile platform BiovitalsHF will be leveraged in the study.

July 17, 2019

Could wearable biosensors change the face of clinical trials and shorten a drug’s regulatory journey? That’s what Yale University and the Mayo Clinic are trying to find out, using biosensors and Biofourmis’ mobile health platform.

July 17, 2019

The current Democratic presidential front-runner plans to use technology and federal funding to help rural communities reduce health disparities.

July 17, 2019

In June, FDA issued a relatively brief draft guidance¹ that may reshape the foundation of drug research and development. In the guidance, FDA urged drugmakers to look beyond gold-standard outcomes such as mortality and hospitalizations in researching and developing new heart failure (HF) medications.

December 1, 2019

Biofourmis, a Singapore digital health startup, said it raised $35 million from investors and will move its headquarters to Boston.

May 21, 2019

Biofourmis, a Singapore-based startup pioneering a distinctly tech-based approach to the treatment of chronic conditions, has raised a $35 million Series B round for expansion.

May 22, 2019

Biofourmis, a Singapore digital health startup, said it raised $35 million from investors and will move its headquarters to Boston.

May 21, 2019

Singaporean startup Biofourmis has raised a $35 million Series B financing round led by to support the growth and commercialization of its digital therapeutics platform and support hiring as the startup moves to its new Boston headquarters.

May 22, 2019

AI-powered Singapore based healthcare IT firm Biofourmis has raised $35 million in Series B funding. The company plans to use these funds in moving its offices from Singapore to Boston along with continuing the expansion of its sales, marketing and technology paradigms. This round takes the total funding to date for the company to $40 million.

May 22, 2019

Biofourmis, a Boston, MA-based digital therapeutics platform, today announced that it has raised $35 million in Series B funding led by Sequoia Capital/Sequoia India and co-led by Mass Mutual. The latest funding round will enable the company to advance its proprietary artificialintelligence (AI)-powered digital therapeutics platform and pipeline that treats and manages a range of complex chronic conditions.

May 21, 2019

Digital therapeutics company Biofourmis announced today that it will be moving its headquarters from Singapore to Boston following the closing of a $35 million Series B financing round.

May 21, 2019

In an age when nearly everyone is digitally connected in some way – even many senior citizens, who are often characterized as technophobic – it only makes sense that the healthcare industry is seeing a lot of connected health devices and remote patient monitoring (RPM) technologies.

May 6, 2020

Three organizations to build a COVID-19 biobank. Biogen, the Broad Institute of the Massachusetts Institute of Technology and Harvard University, and PartnersHealthCare joined forces to create it. They aim to provide scientists with a collection of data on the virus in hopes of aiding treatment and vaccine development.

April 20, 2020

SAN FRANCISCO—It's the last day of the conference, and as things wind down, there's plenty of exhaustion to go around from running to back-to-back meetings.

April 16, 2020

At Biofourmis, we augment Personalized Care and Therapies using Digital Therapeutics

April 16, 2020

Suki, a startup that makes an AI-powered voice assistant for doctors, received two pieces of news from major clients less than three weeks ago. The first was that they’d need the product to accommodate telemedicine visits. The second was that they’d need autofilled clinical notes to quickly process patients who test positive for COVID-19 — “Hey, Suki, write up a completed clinical note for COVID-19.”

April 2, 2020

The coronavirus outbreak has rapidly accelerated the nation’s slow-moving effort to incorporate artificial intelligence into medical care, as hospitals grasp onto experimental technologies to relieve an unprecedented strain on their resources.

March 31, 2020

AI (Artificial Intelligence) has a long history, going back to the 1950s when the computer industry started.  It’s interesting to note that much of the innovation came from government programs, not private industry. This was all about how to leverage technologies to fight the Cold War and put a man on the moon.

March 28, 2020

The coronavirus pandemic is turning economies and our daily lives upside down. Some larger companies that provide home entertainment, hand sanitizers, delivery services, pharmaceutical research and even toilet paper (who would’ve guessed?) are poised to take advantage. But it’s not just these large companies that are benefiting and looking for ways to help.

March 19, 2020

Biofourmis, a developer of digital therapeutics aimed at personalized care, says its technology is being used in a remote-monitoring and disease-surveillance program in Hong Kong involving patients with diagnosed or suspected novel coronavirus disease (COVID-19).

March 13, 2020

Biofourmis, a Boston startup that produces AI-enabled health devices, is aiding in a University of Hong Kong program to monitor and treat coronavirus patients.

March 11, 2020

Hong Kong is set to become the world’s first testing ground for the deployment of devices and data analytics tools to remotely monitor Covid-19 virus patients and others under quarantine.

March 6, 2020

Biofourmis is using its wearable and artificial intelligence technology to aid with disease surveillance and to help researchers better understand the illness.

March 6, 2020

Digital tools such as telehealth, remote patient monitoring, data analytics and even consumer-facing AI-based chatbots could play a key role in containing the outbreak of COVID-19 and help people who think they've been exposed to the novel coronavirus – but experts warn that such tools are not a cure-all.

March 5, 2020

Doctors and researchers in Hong Kong are betting an artificial intelligence-based remote-monitoring system from startup Biofourmis Inc. will aid them in their fight against disease caused by a new coronavirus.

March 4, 2020

Kuldeep Singh Rajput, CEO of Biofourmis, discusses how wearable tech and A.I. can help in the fight against the coronavirus epidemic.

March 4, 2020

Press Release

BOSTON, March 4, 2020 /PRNewswire/ -- Biofourmis, a global leader in digital therapeutics that powers personalized predictive care, announced today that its technology is being leveraged in a remote monitoring and disease surveillance program in Hong Kong involving patients with diagnosed or suspected novel coronavirus disease (COVID-19). The program—administered by The University of Hong Kong—also includes Hong Kong-based Harmony Medical Inc., which is Biofourmis' joint venture partner for the China region.

March 4, 2020

As the novel coronavirus (COVID-19) continues to spread, Boston-based Biofourmis is being leveraged in a remote monitoring and disease surveillance program in Hong Kong involving patients with diagnosed or suspected novel coronavirus disease (COVID-19). The national disease monitoring program—administered by The University of Hong Kong’s Department of Health—also includes Hong Kong-based Harmony Medical Inc., which is Biofourmis’ joint venture partner for the China region.

March 3, 2020

Biofourmis, a fast-growing global health IT start-up founded in Singapore, and ImagineMIC, a New York-based medical device company formed a partnership to drive improved outcomes and lower healthcare costs for patients with chronic conditions. ImagineMIC provides chronic care management through remote monitoring services and HIPAA-compliant technology.

January 31, 2020

PR Newswire

BOSTON, Jan. 30, 2020 /PRNewswire/ -- Biofourmis, a fast-growing global leader in digital therapeutics that powers personally predictive care, and ImagineMIC™ announced a partnership agreement today to drive improved outcomes and lower healthcare costs for patients with chronic conditions. ImagineMIC™ is a revolutionary medical device company that delivers chronic care management through remote monitoring services and HIPAA-compliant technology.

January 30, 2020

Biofourmis, a fast-growing global leader in digital therapeutics that powers personally predictive care, has named two highly experienced and skilled business leaders with deep, highly relevant backgrounds as the company’s chief operating officer (COO) and chief technology officer (CTO).

January 28, 2020

Digital therapeutics deliver evidence-based therapies via software — often in the form of consumer-facing mobile health apps — that replace or complement the existing treatment of a disease. They diverge from the broader digital health market in that they must be approved by regulatory bodies — and displaying proof-of-concept is at the core of their model.

December 18, 2019

Press Release

Biofourmis, which makes software-based therapeutic platforms, has purchased Biovotion, a company that makes a wearable biosensor. The financial details of the cash-and-equity deal were not disclosed but the deal includes more than 60 global patents for wearable and sensor technology. These days — as Google’s purchase of Fitbit shows — data is almost as important, if not more important, than the hardware so even in the case of Biofourmis the data held great interest.

November 18, 2019

Digital therapeutics are one of the biggest drivers of the fast changing healthcare landscape; these software-driven evidence-based therapies can help modify patient behavior, or to intervene earlier based on data collected on the patient through connected devices. These solutions are only becoming more popular, as the global digital therapeutics market is expected to reach $7.8 billion in 2025, up from $1.75 billion in 2017.

November 18, 2019

Press Release

BOSTON and ZÜRICH, Nov. 18, 2019 /PRNewswire/ -- Biofourmis, a fast-growing global leader in digital therapeutics based in Boston, announced today it has reached an agreement to acquire Zürich, Switzerland-based Biovotion AG, a leading developer of a cutting-edge clinical-grade wearable biosensor platform. The acquisition includes all of Biovotion's assets, including the market-leading Everion® biosensor and more than 60 global patents covering most of the wearable and sensor technology that exists for the arm or hand.

November 18, 2019

Press Release

BOSTON, Nov. 18, 2019 /PRNewswire/ -- Biofourmis, a fast-growing global leader in digital therapeutics based in Boston, announced today it has been selected by Novartis, a global healthcare company, to collaborate on a commercial project for managing patients with heart failure (HF) beginning in Southeast Asia, with potential plans to expand globally. The goal of the program is to improve clinical outcomes by using Biofourmis' lead product BiovitalsHF™, which captures data from wearable biosensors and leverages the FDA-cleared Biovitals™ Analytics Engine to identify early signs of HF exacerbations to enable early interventions in patients with HF with reduced ejection fraction.

November 18, 2019

Boston-based Biofourmis has received 510(K) clearance for its machine-learning and artificial intelligence (AI)-powered analytics engine as a medical device for ambulatory physiological monitoring. This regulatory approval is part of the FDA’s growing recognition of machine-learning and AI in the Software as a Medical Device category.

October 4, 2019

Biovitals Analytics Engine, manufactured by Biofourmis, received 510(k) clearance as part of the FDA’s continued recognition of machine learning and AI in the Software as Medical Device category. The company also received approval in May for Biovitals RhythmAnalytics, which they are calling the “Biovitals ecosystem,” the release said.

October 3, 2019

Cision PR Newswire

BOSTON, October 3, 2019 – Biofourmis, a fast-growing global leader in digital therapeutics, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its machine-learning and artificial intelligence (AI)-powered Biovitals™ Analytics Engine as a medical device for ambulatory physiological monitoring. This regulatory approval of the Biovitals™ Analytics Engine is part of FDA's growing recognition of machine-learning and AI in the Software as a Medical Device category.

October 3, 2019

Cision PR Newswire

NEW YORK, Oct. 2, 2019 /PRNewswire/ -- CB Insights announced today at its Future of Health conference that Biofourmis, a Boston-based fast-growing global leader in digital therapeutics, has been named to the organization's inaugural Digital Health 150 ranking, which showcases the 150 most promising private digital health companies in the world. Kuldeep Singh Rajput, CEO and founder of Biofourmis, will be speaking at the Future of Health conference—a gathering of top executives across some of the largest healthcare institutions, startups and investment firms—taking place here today and tomorrow.

October 2, 2019

Markets Insider

BOSTON, Aug. 22, 2019 /PRNewswire/ -- Biofourmis, a fast-growing global leader in digital therapeutics based in Boston, has added two global pharmaceutical senior executive veterans to its executive team to guide the company's worldwide expansion across the pharmaceutical, managed care, healthcare provider and medical technology markets.

August 22, 2019

Becker's Hospital Review

Biofourmis offers a powerful patented AI-based platform for therapeutic decision support. It continuously analyzes data from medical-grade wearable sensors and other patient-generated data to create unique digital biomarkers reflecting the health status of an individual. These digital biomarkers have been assessed in several studies and have demonstrated the ability to help detect changes in an individual’s health status much earlier than previously possible.

July 30, 2019

Press Release

Our data scientist team had recently presented 4 peer-reviewed papers demonstrating clinical effectiveness of #biovitals platform at the International Engineering in Medicine and Biology Conference #EMBC19 - one of the leading Biomedical Conferences! The papers highlighted our clinical study results, in a range of therapeutic areas #heartfailure #sleepapnea #arrhythmias #pain A big kudos to the entire team at Biofourmis! Gengbo Chen Chen Hao Rachel Chan Jiecheng Xie Minghao Yan Reach out to us if you want to learn more!

July 30, 2019

Biofourmis, a digital therapeutics provider, has entered a research partnership with the Yale University-Mayo Clinic Center of Excellence in Regulatory Science and Innovation (CERSI) to help determine if quality of life and functional capacity should be emphasized more in clinical drug trials.

July 19, 2019

Biovotion

In collaboration with the FDA and our partner Biofourmis, Biovotion’s Everion will play a critical role in a new trial aimed at improving outcomes and evaluating new endpoints for heart failure patients. Leveraging Biofourmis’ AI-enabled platform, BiovitalsHF, data collected from discharged patients will be used to develop new methods of evaluating the efficacy of heart failure drugs.

July 19, 2019

Boston’s Biofourmis Inc. is acquiring longtime partner Biovotion, leveraging its software and data-collection capabilities in a new multi-year partnership with Novartis.

July 18, 2019

The Yale University-Mayo Clinic Center of Excellence in Regulatory Science and Innovation has teamed up with digital therapeutics specialist Biofourmis to study the effectiveness of patient-centric endpoints in determining future drug development of heart failure patients.

July 17, 2019

Biofourmis has entered a research partnership with the Yale University-Mayo Clinic Center of Excellence in Regulatory Science and Innovation (CERSI). Biofourmis’ mobile platform BiovitalsHFTM will be leveraged in a study of patients with heart failure to monitor functional capacity and quality of life to see if greater emphasis should be placed on these measures in the drug approval process.

July 17, 2019

Yale University and Rochester, Minn.-based Mayo Clinic are partnering with Bifourmis, a digital therapeutics company, to study the use of patient-measured data to determine effective drug development for heart failure patients.

July 17, 2019

The US Food and Drug Administration is partnering with Yale University and the Mayo Clinic on research into whether a remote patient monitoring platform using mHealth wearables can improve clinical trials that track medication adherence.

July 17, 2019

Press Release

BOSTON, July 16, 2019 /PRNewswire/ -- Biofourmis, a fast-growing global leader in digital therapeutics, has entered a research partnership with the Yale University-Mayo Clinic Center of Excellence in Regulatory Science and Innovation (CERSI). Biofourmis' mobile platform BiovitalsHF^TM will be leveraged in a study of patients with heart failure to monitor functional capacity and quality of life to see if greater emphasis should be placed on these measures in the drug approval process.

July 16, 2019

Fierce Biotech

A collaboration involving the FDA is set to evaluate new endpoints for heart failure clinical trials. The partners will use wearable devices to assess how heart failure patients function and feel after being discharged from hospitals.

July 16, 2019

South China Morning Post

Start-ups such as Boston-based Biofourmis have partnered with local health care platforms like Jianke, giving the company access to its vast customer base

June 9, 2019

Forbes

Biofourmis is a fast-growing global digital health tech start-up that is reinventing remote patient monitoring by combining AI, machine learning...

May 27, 2019

Biofourmis, an AI health IT company based in Singapore, today announced that it’s raised $35 million in a series B financing round led by Sequoia Capital’s Sequoia India and MassMutual Ventures, with participation from Singapore government-linked strategic investor EDBI, Chinese online health care platform Jianke, Openspace Ventures, Aviva Ventures, and SGInnovate. It brings the company’s total raised to over $40 million, according to Crunchbase, and will fuel its ongoing commercialization efforts in the U.S. and Asia and the growth of its data science, clinical and regulatory, and sales and operations teams.

May 21, 2019

This morning, artificial-intelligence-enabled monitoring and decision support platform Biofourmis announced a $35 million Series B raise. The round was led by Sequoia India and MassMutual Ventures with participation from EDBI, Jianke and existing investors Openspace Ventures, Aviva Ventures and SGInnovate.

May 21, 2019

After getting FDA approval to market its first artificial-intelligence cardiac tool, Singapore-based health technology company

May 21, 2019

Tech Crunch

Biofourmis, a Singapore-based startup pioneering a distinctly tech-based approach to the treatment of chronic conditions, has raised a $35 million Series B round for expansion. The round was led by Sequoia India and MassMutual Ventures, the VC fund from Massachusetts Mutual Life Insurance Company. Other investors who put in include EDBI, the corporate investment arm of Singapore’s Economic Development Board, China-based healthcare platform Jianke and existing investors Openspace Ventures, Aviva Ventures and SGInnovate, a Singapore government initiative for deep tech startups. The round takes Biofourmis to $41.6 million raised to date, according to Crunchbase.

May 21, 2019

Mobi Health News

The RhythmAnalytics platform can integrate with medical devices and other ECG management systems to detect arrhythmias.

May 3, 2019

Press Release

Our CEO and Co-Founder Kuldeep Singh Rajput was recently honoured with an invitation to join Milken Institute's Young Leader's Circle (YLC)! The YLC includes over 300 intellectually curious, motivated and philanthropic young professionals between the ages of 25-40, representing the best and brightest from a wide variety of industries. We're extremely proud of you Kuldeep, and can't wait to see what the future holds!

May 3, 2019

Press Release

We're proud to say that our deep learning platform for ECG interpretation, RhythmAnalytics, outperforms a human analysis of an ECG with a high degree of accuracy! (Study link can be found and downloaded here) Congratulations to the team behind this achievement - Kuldeep Singh Rajput, Chen Hao, Sandi Wibowo, Aamani Budhota, Gabriel Azevedo Ferreira, and Maulik Majmundar, M.D. If you're interested in partnership opportunities or learning how our technology works, get in touch with us by clicking the Contact Us button above.

May 3, 2019

Forbes

Congratulations to our Founder and CEO Kuldeep Singh Rajput for making it into the Forbes Asia 30 Under 30 list for Healthcare and Science 2019! We're excited to celebrate this well-deserved achievement as we continue on our mission to predict and prevent critical medical events before they happen!

May 3, 2019

Press Release

BOSTON, March 13, 2019 /PRNewswire/ -- Biofourmis, a fast-growing digital therapeutics company focused on augmenting personalized care and therapies to empower patients with complex chronic conditions, today joined the American Heart Association's Center for Health Technology & Innovation's (Center) Innovators Network to deliver personalized software-based intervention including dose changes, heart failure education and insights to patients with heart failure.

March 13, 2019

Healthcare IT News

Biofourmis, a Singapore-based health analytics platform, has entered into a collaboration with Brigham and Women’s Hospital in Boston, US to co-develop improvements to their proprietary analytics engine, Biovitals™ for Brigham’s Home Hospital Programme.

November 22, 2018

Markets Insider

Mundipharma has announced the development of painfocus™, a revolutionary new end-to-end pain management solution that significantly increases the objectivity of pain measurement, something that has been historically difficult. This has the potential to completely transform how caregivers and doctors manage their patients' pain.

August 5, 2018

PHUSE

Our CEO Kuldeep Singh Rajput will be speaking at PhUSE's first event in Singapore (25th July 2018). Drop by and say hi and let Kuldeep share with you more on our mission to change healthcare.

July 18, 2018

e27

Our COO Karen Wai will be speaking at Echelon Asia Summit 2018 (28 June) on the Topic: “Tackling health problems using AI: Why data analytics will play a big role in healthcare.”

June 21, 2018

TECHINASIA

Singapore-based health analytics platform Biofourmis announced the close of its series A funding round today, while also unveiling a partnership with US medical research institute, the Mayo Clinic.

December 11, 2017

StraitsTimes

SINGAPORE - Singapore-based digital healthtech firm Biofourmis has raised US$5 million (S$6.8 million) in a Series A round of funding from venture capital firm NSI Ventures and Aviva Ventures, the corporate venture arm of insurer Aviva.

December 11, 2017

CNBC

Kuldeep Singh Rajput, CEO of Biofourmis Group, explains how the start-up's health platform looks at changes in a patient's physiological data.

December 10, 2017

TECHINASIA

The company bills itself as the world’s first personalized physiological data analytics firm, and today it announced a fundraise of US$1 million. The round was led by healthcare technology company SpesNet and social innovation firm Eden Strategy. It was joined by angel investors from the healthcare space.

August 10, 2016